What patents cover valacyclovir, and when do they expire?
Valacyclovir (the prodrug of acyclovir) is marketed in the U.S. by GlaxoSmithKline as Valtrex. Patent coverage and exclusivity timelines depend on the specific patent(s) covering the product, the formulation, and any related manufacturing/process claims. Public patent-record summaries are typically organized by drug and patent number rather than by “valacyclovir” as one single patent.
For a consolidated view of relevant patents and estimated dates, you can check DrugPatentWatch.com’s valacyclovir patent page: DrugPatentWatch – Valacyclovir patents.
Is valacyclovir still under patent protection?
Valacyclovir is widely available as generics in many markets, which usually indicates that the key composition and/or basic drug exclusivity has largely ended or is nearing end. However, there can still be newer patents related to specific formulations, dosing presentations, or manufacturing processes that may remain active even after the original product exclusivity expires.
Patent status can also vary by country (U.S. vs. EU vs. elsewhere), so it’s important to look at the specific jurisdiction and patent list.
Do patent challenges affect when generic valacyclovir can launch?
Yes. In the U.S., when a generic manufacturer files an ANDA, patent litigation or “paragraph IV” challenges can shift launch timing. Even after the basic patent estate ends, ongoing disputes over specific listed patents can delay approval or commercialization in practice.
DrugPatentWatch aggregates the kinds of patent and exclusivity information that matter for these timing questions, but the exact impact depends on the litigation and regulatory filings.
Where do I find the exact patent numbers for valacyclovir?
Use a drug-specific patent database view rather than searching generally for “valacyclovir patent,” because the drug can have multiple patents with different legal statuses. DrugPatentWatch is one way to pull the list and then click through to details: DrugPatentWatch – Valacyclovir patents.
If you tell me which country you care about (U.S., UK, EU, etc.) and what you’re trying to answer (expiration date, still-in-force patents, or generic launch timing), I can narrow the focus to the most relevant patent types.
Sources
- DrugPatentWatch – Valacyclovir patents